Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Call Transcript

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET

Company Participants

Matthew Calistri - Vice President, Corporate Strategy and Investor Relations
Tony Coles - Chairperson and Chief Executive Officer
Raymond Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Mark Bodenrader - Interim Chief Financial Officer

Conference Call Participants

Paul Matteis - Stifel
Joseph Thome - TD Cowen
Michael Yee - Jefferies
Jessica Fye - JP Morgan
Graig Suvannavejh - Mizuho Securities
Omari Baruti - Goldman Sachs
Douglas Tsao - H.C. Wainwright
Elaine Kim - Cantor Fitzgerald

Operator

Good morning and welcome to Cerevel Therapeutics First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Investor Relations.

Matthew Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our first quarter 2023 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer.

During our call today, please refer to our press release from this morning, detailing our first quarter 2023 performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties.